Alacizumab is a human monoclonal antibody targeting KDR (VEGFR2). Alacizumab can be used for angiogenesis and oncology research, particularly studies involving VEGF/VEGFR signaling pathways.
T9901A-1995
* VAT and and shipping costs not included. Errors and price changes excepted
